深夜开炮！华熙生物发文驳斥 “玻尿酸过时论”，多家券商研报被点名

Core Viewpoint - The article published by Huaxi Biological refutes the notion that hyaluronic acid is "outdated," arguing that this perspective is a product of "impatient capital" attempting to divert attention from the necessary evolution of China's industry [1][2]. Group 1: Industry Analysis - The rise of the "hyaluronic acid is outdated" theory is characterized as a mirage created by certain capital forces, aiming to shift focus towards new investment themes and companies [2]. - Huaxi Biological directly names several brokerage research reports, including those from Western Securities, which have contributed to the spread of misleading comparisons against the hyaluronic acid industry [2][3]. - The misleading conclusions associated with the "hyaluronic acid is outdated" narrative have been widely disseminated by media and influencers, damaging the market foundation of a competitive Chinese industry [3]. Group 2: Company Performance - Huaxi Biological's stock, once reaching a peak of 309.43 yuan per share, has been on a downward trend since July 2021, closing at 50.6 yuan per share on May 19, with a slight increase of 0.22% [3]. - The company staff indicated that stock price fluctuations are influenced by a combination of factors, and they have not yet experienced any legal disputes related to the article [3].